FDA approves Pfizer's Litfulo as breakthrough treatment for severe alopecia in adolescents.
TL;DR Summary
Pfizer's Litfulo has been approved by the FDA for the treatment of alopecia areata in people aged 12 and above. The drug is also being tested for vitiligo, ulcerative colitis, and Crohn's disease. Regulatory decisions are expected in the EU, UK, Canada, and Japan later this year.
- Pfizer's alopecia tablet approved by FDA in adults and teens, winning broader market than Lilly's Olumiant Endpoints News
- New Hair Loss Drug Approved by FDA Technology Networks
- Pfizer's Litfulo boasts an alopecia edge over Lilly's Olumiant FiercePharma
- FDA Approves Pfizer's Ritlecitinib for Treatment of Alopecia Areata in Adolescents Pharmacy Times
- Pfizer’s Litfulo approved by FDA as first treatment for adolescents with severe alopecia areata PMLiVE
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
55%
104 → 47 words
Want the full story? Read the original article
Read on Endpoints News